Management of High LDL and Borderline Low HDL Cholesterol

Risk Stratification

The American Diabetes Association recommends that patients with high LDL cholesterol and borderline low HDL initiate statin therapy as first-line treatment to aggressively lower LDL to <100 mg/dL, and if HDL remains <40 mg/dL after achieving LDL goals, consider adding a fibrate such as fenofibrate 1, 2
High-risk LDL is defined as ≥130 mg/dL, and borderline HDL is defined as 40-59 mg/dL (or 50-69 mg/dL for women) 3, 4
Optimal targets are LDL <100 mg/dL and HDL >40 mg/dL (>50 mg/dL for women) 1, 3

The American Heart Association recommends that patients with LDL ≥130 mg/dL initiate statin therapy, and for those with existing cardiovascular disease, peripheral vascular disease, or cerebrovascular disease, initiate statin therapy if LDL ≥100 mg/dL 3, 2, 5
For patients with LDL >125 mg/dL above goal, start pharmacotherapy simultaneously with lifestyle modifications rather than waiting 3-6 months 1, 4
Do not delay pharmacotherapy if LDL exceeds goal by >25 mg/dL, particularly in high-risk patients 1, 4

HMG-CoA reductase inhibitors (statins) are the first-choice agents for LDL lowering, reducing LDL by 30-60% depending on dose, and modestly increasing HDL by approximately 5-7% 1, 6, 5
High-dose statins provide additional triglyceride reduction if needed 2, 5
If HDL remains <40 mg/dL after achieving LDL goals, consider adding fenofibrate as the preferred fibrate for combination therapy 1, 6, 2

When both LDL and HDL abnormalities persist, the first choice is high-dose statin alone, the second choice is statin plus fibrate (fenofibrate preferred over gemfibrozil), and the third choice is statin plus niacin (requires careful monitoring) 6, 5, 1
The combination of statins with fibrates (especially gemfibrozil) or niacin carries increased risk of myositis, but fenofibrate is safer than gemfibrozil for combination therapy with statins 1, 6, 5

Reassess lipids at 4-6 week intervals after initiating or adjusting therapy, and annually once stable on therapy 6, 2, 3, 5
Monitor for statin side effects, such as muscle symptoms and liver enzymes, and if using niacin, monitor glucose levels closely 1, 2